Skip to main content
. 2017 Sep 30;8(49):86747–86768. doi: 10.18632/oncotarget.21421

Figure 7. Specific binding of PFT to v6A3 cells in vitro.

Figure 7

(A) Flow cytometry analysis of PFT binding to the 1:1 mixture of PC3M (SORE6-GFP-) and v6A3 (SORE6-GFP+) cells. Two gates were set up based on the GFP signal (x axis) to separate PC3M and v6A3 cells. The cell bound biotinylated peptides were detected by APC conjugated streptavidin. The MFI of APC signal (y axis) detected from each gate was calculated to present the PFT binding level. (B) Normalized PFT binding levels were calculated as the ratio of MFI of v6A3 (gray bar) to those of PC3M (white bar) cells. The data presented in each group are the averages with standard deviations from triplicate samples. ***, P < 0.001. (C) Confocal fluorescence microscopy assay of PFT binding in the mixed culture of PC3M and v6A3 cells (green). Cell bound biotinylated PFT was detected by PE conjugated streptavidin (red). Cell nuclei were stained by DAPI (blue). (D) Confocal fluorescence microscopy assay of GFP images of paraffin-embedded v6A3 tumor xenografts from mice. The SORE6-GFP positive cells (green) were stained by FITC-conjugated anti-GFP Ab and cell nuclei were stained by DAPI (blue). Scale bar, 50 μm.